Teva Pharmaceutical Industries Limited : Phase IIa Laquinimod Trial Results Show Positive Data for Potential Use in Active Crohn’s Disease

Newly Presented Data at 20 th United European Gastroenterology (UEG) Week Conference Show Significant Impact of Laquinimod on Clinical Remission versus Placebo Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI …

Share